How to Evaluate a Pharmacy Lien Provider Before Recommending One

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | November 13, 2024 | 10 min read

Not all pharmacy lien providers are equal — and experienced adjusters know the difference. The quality of clinical documentation determines whether a lien holds up at settlement or becomes a target. Here is the due diligence framework every PI attorney should apply before recommending a pharmacy partner.

How to Evaluate a Pharmacy Lien Provider Before Recommending One

Personal injury attorneys sometimes hesitate to suggest pharmacy lien providers to clients. The concern is understandable: a provider whose documentation does not hold up at settlement reflects on the attorney, can complicate lien negotiations, and — in the worst case — gives defense counsel an opening to challenge the entire treatment narrative.

The good news is that this risk is manageable with straightforward due diligence. The problem is not pharmacy liens. The problem is that documentation quality varies significantly across providers, and adjusters learn quickly which providers' liens they can challenge and which they cannot.

[!KEY] Adjusters know which pharmacy lien providers have defensible documentation and which ones don't — the provider you choose affects how seriously the adjuster treats the entire medication damages claim.

Why Documentation Quality Is the Decisive Factor

Pharmacy lien providers are not all running the same operation. The core service — dispensing medications and deferring payment to settlement — is structurally similar across the market. What varies dramatically is the clinical documentation layer:

• Who reviews whether the prescribed medications are appropriate?
• Is there a clinical narrative explaining why each medication was prescribed?
• Does the documentation connect prescriptions to the specific accident diagnoses, or simply list drugs dispensed?
• Is the documentation written as a neutral clinical assessment, or does it read as advocacy for the highest possible settlement?

Adjusters and defense attorneys have worked enough pharmacy lien cases to recognize the difference. A lien backed by generic records and no pharmacist analysis will be challenged. A lien backed by patient-specific clinical documentation from a licensed pharmacist will be defended.

Six Questions to Ask Before Recommending a Provider

1. Does a licensed pharmacist review every case?

Dispensing medications is not the same as reviewing whether the medications are clinically appropriate. A provider that processes high case volumes without pharmacist review is essentially a billing operation, not a clinical one.

Ask specifically: Is a licensed pharmacist (RPh or PharmD) assigned to review each patient's medication profile? Does that review include assessment for clinical appropriateness, drug-drug interactions, and alignment between the prescribed medications and the documented injury diagnoses?

A provider without pharmacist oversight has no clinical credential behind its documentation. When challenged, there is no expert to stand behind the records.

2. Is the clinical narrative patient-specific, or a template?

Every pharmacy lien should come with a clinical narrative explaining the medical rationale for the medications prescribed. The question is whether that narrative is individualized.

A template narrative — the same language repeated across hundreds of cases with the patient's name swapped in — will not survive scrutiny. A competent defense attorney will obtain examples of the provider's documentation from other cases and show that the "clinical assessment" is boilerplate.

A patient-specific narrative identifies the patient's documented injuries, explains how each prescribed medication addresses those injuries, cites the treating physician's diagnoses, and is signed by a pharmacist who has actually reviewed the chart.

3. Does documentation establish causation — or just transaction records?

Standard dispensing records show what was dispensed, when, and in what quantity. They document the transaction. They do not document causation.

For a medication to be compensable in a PI settlement, the opposing side needs to understand why it was prescribed in the context of this accident. Medication records that simply list drugs dispensed are susceptible to the argument that the prescriptions pre-date the accident, relate to a pre-existing condition, or were prescribed for a reason unrelated to the injury.

Defensible documentation connects each prescription to the accident-related diagnoses documented by the treating physicians. This connection requires clinical analysis — not just a printout.

4. Are medication choices clinically justified for this patient's injury profile?

One pattern adjusters have learned to identify: medication profiles that look identical regardless of the patient's injuries. A patient with soft tissue injuries and a patient with nerve damage and post-traumatic migraine should not be on the same set of medications. When they are, it signals that someone is optimizing for lien value rather than treating the patient.

A credible pharmacy partner should be able to explain, medication by medication, why this patient on this injury profile is receiving this specific drug. If the clinical rationale cannot survive that question, the lien cannot survive it either.

5. Does the provider cooperate in lien negotiations?

A provider that is inflexible in lien negotiations — refusing to reduce or compromise even when the clinical justification for specific medications is genuinely disputed — creates unnecessary friction at settlement and can delay resolution for the client.

Ask attorneys who have used the provider: Does the provider engage reasonably in negotiation when specific line items are contested? Does it distinguish between medications that are clearly documented and supported versus those where the clinical case is weaker?

Providers that hold firm on every dollar regardless of merit are creating adversarial dynamics that make settlements harder and attract scrutiny to the entire lien.

6. Are the lien terms genuinely non-recourse?

[!WARNING] Read the non-recourse provision in the lien agreement carefully — vague language like "subject to review" or "at provider's discretion" is not the same as a clean unconditional waiver.

This is the structural question. If there is no recovery, the lien should be waived in full — not reduced, not converted to a personal obligation. The waiver should be in writing in the lien agreement, not verbal assurance.

Read the agreement. The non-recourse provision should be explicit: if the case does not resolve, or resolves for insufficient funds, the provider waives its claim. Any language that hedges this — "in LienScripts' discretion," "subject to review," or similar — is a flag.

This is also the basis on which you can recommend the lien to your client with confidence. A truly non-recourse lien is a risk-free option for the client. Anything less is not.

What Adjuster-Flagged Providers Have in Common

Experienced adjusters and defense counsel develop opinions about which pharmacy lien providers have credible documentation and which do not. Providers that consistently face challenges tend to share characteristics:

Generic documentation with no clinical layer. If every lien from a provider looks identical regardless of the patient's injury profile, it is being challenged on medical necessity in every case.

No pharmacist credential behind the documentation. A dispensing pharmacy that provides records but no clinical analysis gives defense counsel nothing to defend against when they argue the medications were unnecessary.

Documentation that reads as advocacy, not assessment. Clinical documentation that is calibrated to support the highest possible lien value — rather than to accurately describe the patient's treatment — is detectable. Adjusters who read hundreds of these documents recognize the pattern.

Unusual medication patterns. Profiles that include expensive specialty medications for injury types that would not typically warrant them signal that someone other than a clinician is driving medication selection.

[!KEY] A template clinical narrative — the same boilerplate language across hundreds of cases with only the patient's name swapped in — will not survive scrutiny from a competent defense attorney who requests examples of the provider's documentation from other cases.

Neutral Clinical Assessment Is What Holds Up

The single most important quality indicator for a pharmacy lien provider is whether its documentation is a neutral clinical assessment or an advocacy document.

A neutral clinical assessment documents what a pharmacist determined was clinically appropriate for this patient's injuries at the time of each prescription. It identifies the clinical rationale, connects it to the treating physician's diagnoses, notes any clinical concerns, and is signed by a pharmacist who will stand behind it. It does not inflate. It does not omit clinical concerns to strengthen the narrative. It accurately represents the standard of care.

This kind of documentation is harder to attack precisely because it was not built to be unassailable. It was built to be accurate. When a defense attorney challenges it, the pharmacist who wrote it can testify to the clinical reasoning without contradiction, because the documentation already reflects that reasoning honestly.

Advocacy documents, by contrast, are often internally inconsistent with the clinical record — and cross-examination exposes the gap.

[!KEY] Neutral clinical documentation — written to accurately describe the patient's treatment rather than to maximize lien value — is harder to attack precisely because the pharmacist can testify to the clinical reasoning without contradiction, while advocacy documents expose internal inconsistencies under cross-examination.

Performing Due Diligence as a Matter of Practice

Asking these questions before recommending a provider is appropriate professional practice. You are evaluating a service that will generate documentation in cases you are responsible for. The evaluation is not different in kind from evaluating a medical expert before using them, or a lien funding company before recommending one.

For the attorney who referred the law firm question that prompted this article: you are right to ask. The answer is that the due diligence is straightforward and the right partners will welcome the scrutiny.

Contact LienScripts to discuss our documentation standards and clinical pharmacist oversight program.

Related Resources

• Top Adjuster Attacks on Pharmacy Liens — And How to Rebut Them
• Why Some Pharmacy Liens Face More Challenges Than Others
• Can You Recommend a Pharmacy Lien Provider Without Creating Liability?
• The Role of a Clinical Pharmacist in Personal Injury Cases